{"entity":{"id":"nct07450599","kind":"trial","name":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi","aka":["CHINANEO"],"tldr":"A phase 2 trial of Darolutamide in prostate cancer, run by Bayer, now recruiting.","summary":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. is a phase 2 interventional study registered as NCT07450599 by Bayer, with 250 participants planned, started 2026-04-27 and due to reach its primary completion in 2028-10-15. Interventions recorded: Darolutamide, ADT. Conditions listed: High-risk Localized Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07450599","url":"https://clinicaltrials.gov/study/NCT07450599"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-high-risk"],"sections":[],"technologies":["androgen-deprivation"],"targets":[],"drugs":["darolutamide"],"companies":["bayer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07450599","phase":"2","setting":"A China Interventional Phase II, Single Arm, Multicenter Study Evaluating the Effectiveness and Safety of Darolutamide + ADT as Neo-Adjuvant Treatment in Treatment-naïve Patients Who Have Planned for Radical Prostatectomy (RP) With High Risk Localized Prostate Cancer","sponsor":"Bayer","participation":[{"nct":"NCT07450599","source":"https://clinicaltrials.gov/study/NCT07450599","fetchedAt":"2026-10-07T16:55:45.930Z","studySha256":"f60cdec616e38958e2a1824e94efcb3f3828ecd1b8fec1f318889ac888a021fd","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-10","leadSponsor":"Bayer","collaboratorCount":0,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":250,"enrolmentType":"ESTIMATED","siteCount":23,"recruitingSiteCount":6,"countries":["China"]}],"started":"2026-04-27","startedType":"actual","enrolled":250,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07450599/","neighbours":{"cancer":[{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/"}],"drug":[{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/"}],"company":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/"}]}}